Candel Therapeutics, Inc. (CADL)
NASDAQ: CADL · Real-Time Price · USD
5.13
+0.19 (3.85%)
At close: Mar 9, 2026, 4:00 PM EDT
5.18
+0.05 (0.97%)
After-hours: Mar 9, 2026, 5:48 PM EDT
Candel Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
38
Market Cap
375.76M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ginkgo Bioworks Holdings | 170.16M |
| Bicycle Therapeutics | 28.34M |
| LENZ Therapeutics | 17.50M |
| Aclaris Therapeutics | 7.83M |
| Absci | 2.82M |
| Shattuck Labs | 1.00M |
| Neurogene | 925.00K |
CADL News
- 18 hours ago - Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting - GlobeNewsWire
- 7 days ago - Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 13 days ago - Candel Therapeutics to Present at TD Cowen's 46th Annual Health Care Conference in Boston - GlobeNewsWire
- 17 days ago - Stock Market Today: Dow Jones, S&P 500 Futures Rise Ahead Of Q4 GDP Numbers—Grail, Candel Therapeutics, Copart In Focus - Benzinga
- 18 days ago - Candel Therapeutics Announces Pricing of Public Offering - GlobeNewsWire
- 18 days ago - Candel Therapeutics Announces Proposed $100 Million Public Offering - GlobeNewsWire
- 18 days ago - Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer - GlobeNewsWire
- 26 days ago - Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit - GlobeNewsWire